References

Conti, R. M., W. V. Padula, and R. A. Larson. 2016. Changing the cost of care for chronic myeloid leukemia: The availability of generic imatinib in the USA and the EU. Annals of Hematology 94(2):249–257.

Cutler, D. M., and R. J. Zeckhauser. 2000. The anatomy of health insurance. Handbook of Health Economics 1:563–643.

Daniels, N. 2007. Just health: Meeting health needs fairly. New York: Cambridge University Press.

Danzon, P. 2014. Pricing and reimbursement of biopharmaceuticals and medical devices in the USA. Encyclopedia of Health Economics 3:127–135.

De George, R. T. 2005. Intellectual property and pharmaceutical drugs: An ethical analysis. Business Ethics Quarterly 15(04):549–575.

Dunfee, T. W. 2006. Do firms with unique competencies for rescuing victims of human catastrophes have special obligations? Corporate responsibility and the AIDS catastrophe in sub-Saharan Africa. Business Ethics Quarterly 16(2):185–210.

Dusetzina, S. B. 2016. Drug pricing trends for orally administered anticancer medications reimbursed by commercial health plans, 2000–2014. JAMA Oncology 2(7):960–961.

Dusetzina, S. B., and N. L. Keating. 2015. Mind the gap: Why closing the doughnut hole is insufficient for increasing Medicare beneficiary access to oral chemotherapy. Journal of Clinical Oncology 34(4):375–380.

Elegido, J. M. 2015. The just price as the price obtainable in an open market. Journal of Business Ethics 130(3):557–572.

Elhauge, E. 2005. Sacrificing corporate profits in the public interest. New York University Law Review 80:733.

Express Scripts. 2017. The Express Scripts 2016 drug trend report. http://lab.express-scripts.com/lab/drug-trend-report.

Frederick, S., G. Loewenstein, and T. O’Donoghue. 2002. Time discounting and time preference: A critical review. Journal of Economic Literature 40(2):351–401.

Fried, I., A. L. Beam, I. S. Kohane, and N. P. Palmer. 2017. Utilization, cost, and outcome of branded vs. compounded 17-alpha hydroxyprogesterone caproate in prevention of preterm birth. JAMA Internal Medicine.https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2655241.

Friedman, M. 2009. Capitalism and freedom. Chicago: University of Chicago Press (Reprint edition).

Hale, V. G., K. Woo, and H. L. Lipton. 2005. Oxymoron no more: The potential of nonprofit drug companies to deliver on the promise of medicines for the developing world. Health Affairs 24(4):1057–1063.

Hartman, M., A. B. Martin, D. Lassman, A. Catlin, and National Health Expenditure Accounts Team. 2015. National health spending in 2013: Growth slows, remains in step with the overall economy. Health Affairs 34(1):150–160.

Heath, J. 2014. Morality, competition, and the firm: The market failures approach to business ethics. New York: Oxford University Press.

Hsieh, N.-h. 2009. Corporate social responsibility and the priority of shareholders. Journal of Business Ethics 88:553–560.

IOM (Institute of Medicine). 2009. The U.S. commitment to global health: Recommendations for the public and private sectors. Washington, DC: The National Academies Press.

Kamal-Yanni, M. 2015. Hepatitis C drug affordability. The Lancet Global Health 3(2):e73–e74.

Kanavos, P., A. Ferrario, S. Vandoros, and G. F. Anderson. 2013. Higher U.S. branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs. Health Affairs 32(4):753–761.

Kantor, E. D., C. D. Rehm, J. S. Haas, A. T. Chan, and E. L. Giovannucci. 2015. Trends in prescription drug use among adults in the United States from 1999–2012. JAMA 314(17):1818–1830.

Keehan, S. P., D. A. Stone, J. A. Poisal, G. A. Cuckler, A. M. Sisko, S. D. Smith, A. J. Madison, C. J. Wolfe, and J. M. Lizonitz. 2017. National health expenditure projections, 2016–25: Price increases, aging push sector to 20 percent of economy. Health Affairs 36(3):553–563.

Kesselheim, A. S., J. Avorn, and A. Sarpatwari. 2016. The high cost of prescription drugs in the United States: Origins and prospects for reform. JAMA 316(8):858–871.

KFF (Kaiser Family Foundation). 2017a. Kaiser health tracking poll: Health care priorities for 2017. http://www.kff.org/health-costs/poll-finding/kaiser-health-tracking-poll-healthcare-priorities-for-2017.

KFF. 2017b. Public opinion on prescription drugs and their prices. http://www.kff.org/slideshow/public-opinion-on-prescription-drugs-and-their-prices.

Lynch, J., and S. E. Gollust. 2010. Playing fair: Fairness beliefs and health policy preferences in the United States. Journal of Health Politics, Policy and Law 35(6):849–887.

Mackey, T. K., B. A. Liang, R. Cuomo, R. Hafen, K. C. Brouwer, and D. E. Lee. 2014. Emerging and reemerging neglected tropical diseases: A review of key characteristics, risk factors, and the policy and innovation environment. Clinical Microbiology Reviews 27(4):949–979.

Maitland, I. 2002. Priceless goods: How should life-saving drugs be priced? Business Ethics Quarterly 12(04):451–480.

Nagel, T. 2005. The problem of global justice. Philosophy & Public Affairs 33(2):113–147.

NCI (National Cancer Institute). 2017. PDQ financial toxicity and cancer treatment.https://www.cancer.gov/about-cancer/managing-care/track-care-costs/financial-toxicity-hp-pdq.

Newhouse, J. P. 1988. Has the erosion of the medical marketplace ended? Journal of Health Politics, Policy and Law 13(2):263–278.

Phelps, C. 2018. Health economics. 6th Edition. New York: Routledge Press.

Politico. 2017. Americans’ top priorities for Congress through the end of the year. https://www.politico.com/f/?id=0000015e-7bce-d079-a3fe-7bce31540000.

QuintilesIMS. 2016. Medicines use and spending in the U.S.: A review of 2015 and outlook to 2020. Parsippany, NJ: QuintilesIMS Institute.

QuintilesIMS. 2017. Medicines use and spending in the U.S.: A review of 2016 and outlook to 2021. Parsippany, NJ: QuintilesIMS Institute.

Ramsey, S., D. Blough, A. Kirchhoff, K. Kreizenbeck, C. Fedorenko, K. Snell, P. Newcomb, W. Hollingworth, and K. Overstreet. 2013. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Affairs 32(6):1143–1152.

Rawls, J. 1971. A theory of justice. Cambridge, MA: Harvard University Press.

Reuters. 2014. Sanofi rolls out large-scale supply of synthetic malaria drug. http://www.reuters.com/article/health-malaria-sanofi/sanofi-rolls-out-large-scale-supply-of-syntheticmalaria-drug-idUSL6N0QI1B020140812.

Rosenblatt, M. 2017. The large pharmaceutical company perspective. New England Journal of Medicine 376(1):52–60.

Rosenblatt, M., and H. Termeer. 2017. Reframing the conversation on drug pricing, New England Journal of Medicine Catalyst, October 19. https://catalyst.nejm.org/reframingconversation-drug-pricing.

Scherer, F. M. 2000. The pharmaceutical industry. Handbook of health economics 1:1297–1336.

Taurel, S. 2005. The campaign against innovation. In Ethics and the pharmaceutical industry. Cambridge, UK: Cambridge University Press. Pp. 326–335.

Vagelos, P. R. 1991. Are prescription drug prices high? Science 252(5009):1080–1084.

Vagelos, P. R., and L. Galambos. 2004. Medicine, Science and Merck. Cambridge, UK: Cambridge University Press.

Valdman, M. 2009. A theory of wrongful exploitation. Philosophers’ Imprint 9(6):1–14.

CHAPTER 2

AACR (American Association for Cancer Research). 2011. AACR cancer progress report 2011. Clinical Cancer Research 22(19 Suppl):S1–S137.

AISHealth. 2016. Profiles of the eight largest health insurers: 2016.https://aishealth.com/sites/all/files/bp82016.pdf.

Anderson, J. L., P. A. Heidenreich, P. G. Barnett, M. A. Creager, G. C. Fonarow, R. J. Gibbons, J. L. Halperin, M. A. Hlatky, A. K. Jacobs, and D. B. Mark. 2014. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures. Circulation 129(22):2329–2345.

Arrowsmith, J. 2011. Trial watch: Phase III and submission failures: 2007–2010. Nature Reviews Drug Discovery 10(2):87.

Arrowsmith, J., and P. Miller. 2013. Trial watch: Phase II and phase III attrition rates 2011–2012. Nature Reviews Drug Discovery 12(8):569.

Balto, D. 2014. Testimony of David A. Balto before the Employee Benefits Security Administration Advisory Council on Employee Welfare and Pension Benefit Plans, U.S. Department of Labor. Hearing on section 408(b)(2) regulation: PBM compensation and fee disclosure. June 19.

Balto, D. 2015. Testimony of David A. Balto before the House Judiciary Subcommittee on Regulatory Reform, Commercial and Antitrust Law. Hearing on The State of Competition in the Pharmacy Benefits Manager and Pharmacy Marketplaces. November 17.

Balto, D. 2017. Testimony of David A. Balto before the California Senate Committee on Business, Profession and Economic Development. Hearing Section on Pharmacy Benefit Managers 101. March 20.

Barclays Bank PLC. 2017. The equity research report—U.S. health care distribution & technology: How do PBMs make money? March 7. New York: Barclays Capital, Inc.

Barlas, S. 2016. Health plans and drug companies dip their toes into value-based pricing: The pressure is on P&T committees to monitor utilization. Pharmacy and Therapeutics 41(1):39–53.

BLS (U.S. Bureau of Labor Statistics). 2016. Distribution of private sector employment by firm size class: 1993/Q1 through 2016/Q1, not seasonally adjusted. http://www.bls.gov/web/cewbd/table_f.txt.

Boumil, M. M., and G. D. Curfman. 2013. On access and accountability—Two Supreme Court rulings on generic drugs. New England Journal of Medicine 369(8):696–697.

Brill, A. 2014. Lost prescription drug savings from use of REMS programs to delay generic market entry. Matrix Global Advisers. http://www.gphaonline.org/media/cms/REMS_Studyfinal_July2014.pdf.

Carrier, M. A., and S. D. Shadowen. 2016. Product hopping: A new framework. Notre Dame Law Review 92:167.

CBO (U.S. Congressional Budget Office). 2014. Competition and the cost of Medicare’s prescription drug program. Washington, DC: Congressional Budget Office.

Channick, S. A. 2006. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003: Will it be good medicine for U.S. health policy? Elder Law Journal 14:237.

Chen, L. 2015. The most profitable industries in 2016.https://www.forbes.com/sites/liyanchen/2015/12/21/the-most-profitable-industries-in-2016/#3c3ba5d15716.

CMS (Centers for Medicare & Medicaid Services). 2015. CMS releases 2014 national health expenditures. https://www.cms.gov/Newsroom/MediaReleaseDatabase/Pressreleases/2015-Press-releases-items/2015-12-02.html.

CMS. 2016. 2016 annual report of the boards of trustees of the Federal Hospital Insurance and Federal Supplementary Medical Insurance trust funds.https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/ReportsTrustFunds/downloads/tr2016.pdf.

CMS. 2017. Medicare Part D–Direct and Indirect Remuneration (DIR). https://www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-sheets/2017-Fact-Sheet-items/2017-01-19-2.html.

Cohen, S., and W. Yu. 2012. The concentration and persistence in the level of health expenditures over time: Estimates for the U.S. population, 2008–2009. Statistical brief #354. http://www.January.meps.ahrq.gov/data_files/publications/st354/stat354.pdf.

Cook, A., T. Kornfield, and M. Gold. 2000. The role of PBMs in managing drug costs: Implications for a Medicare drug benefit: Menlo Park, CA: Henry J. Kaiser Family Foundation.

Credit Suisse. 2017. Equity research. Global pharmaceuticals & biotechnology report. April 18.https://research-doc.credit-suisse.com/docView?language=ENG&format=PDF&sourceid=em&document_id=1073763651&serialid=%2FoS2%2F%2Buhfn1K9jHaHOw40qPqJMxew63e%2F6kudOybyhM%3D.

Deloitte, L. L. P. 2016. Measuring the return from pharmaceutical innovation, 2016.http://www2.deloitte.com/uk/en/pages/life-sciences-and-healthcare/articles/measuring-returnfrom-pharmaceutical-innovation.html.

DeMartino, J. K., and J. K. Larsen. 2012. Equity in cancer care: Pathways, protocols, and guidelines. Journal of the National Comprehensive Cancer Network 10(Suppl 1):S-1–S-9.

Duggan, M., and F. Scott Morton. 2010. The effect of Medicare Part D on pharmaceutical prices and utilization. American Economic Review 100(1):590–607.

Dusetzina, S. B., and N. L. Keating. 2015. Mind the gap: Why closing the doughnut hole is insufficient for increasing Medicare beneficiary access to oral chemotherapy. Journal of Clinical Oncology 34(4):375–380.

Dusetzina, S. B., R. M. Conti, L. Y. Nancy, and P. B. Bach. 2017. Association of prescription drug price rebates in Medicare Part D with patient out-of-pocket and federal spending. JAMA Internal Medicine 177(8):1185–1188.

Dwivedi, G., S. Hallihosur, and L. Rangan. 2010. Evergreening: A deceptive device in patent rights. Technology in Society 32(4):324–330.

EBRI (Employee Benefit Research Institute). 2016. Self-insured health plans: Recent trends by firm size, 1996–2015. http://www.ebri.org/pdf/notespdf/EBRI_Notes_07-no7-July16.Self-Ins.pdf.

The Economist. 2002. Innovation’s golden goose. January 12. http://www.economist.com/node/1476653.

Eickelberg, H. 2015. The prescription drug supply chain “black box”: How it works and why you should care. Washington, DC: American Health Policy Institute.

FDA (U.S. Food and Drug Administration). 2006. Guidance for industry, investigators, and reviewers: Exploratory IND studies. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm078933.pdf.

FDA. 2015. FDA’s drug review process. http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm289601.htm.

FDA. 2016. CFR—Code of federal regulations. Title 21. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.21.

FDA. 2017a. Step 3: Clinical research. http://www.fda.gov/forpatients/approvals/drugs/ucm405622.htm.

FDA. 2017b. FDA basics webinar: A brief overview of risk evaluation and mitigation strategies (REMS). https://www.fda.gov/AboutFDA/Transparency/Basics/ucm325201.htm.

Feldman, R., and C. Wang. 2017. May your drug price be ever green.https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3061567.

Frakt, A. B. 2016. Determining value and price in health care. JAMA 316(10):1033–1034.

Frank, R., and R. J. Zeckhauser. 2017. A framework for negotiation in Part D of Medicare. Hutchins Center Working Papers. https://www.brookings.edu/wp-content/uploads/2017/05/wp28_frankzeckhauser_medicarepartd.pdf.

FTC (Federal Trade Commission). 2004. Letter to assembly member Greg Aghazarian. September 7. http://www.ftc.gov/sites/default/files/documents/advocacy_documents/ftccomment-hon.greg-aghazarian-concerning-ca.b.1960-requiring-pharmacy-benefit-managers-make-disclosures-purchasers-and-prospective-purchasers/v040027.pdf.

FTC. 2006. Letter to delegate Terry G. Kilgore. October 2. http://www.ftc.gov/sites/default/files/documents/advocacy_documents/ftc-staff-comment-hon.terry-g.kilgore-concerningvirginia-house-bill-no.945-regulate-contractual-relationship-between-pharmacy-benefitmanagers-and-both-health-benefit/v060018.pdf.

FTC. 2009. Letter to Senator James L. Seward. March 31. http://www.ftc.gov/sites/default/files/documents/advocacy_documents/ftc-staff-comment-honorable-james-l.sewardconcerning-new-york-senate-bill-58-pharmacy-benefit-managers-pbms/v090006newyorkpbm.pdf.

FTC. 2011. Letter to The Honorable Mark Formby. March 22. http://www.ftc.gov/sites/default/files/documents/advocacy_documents/ftc-staff-letter-honorable-mark-formbymississippi-house-representatives-concerning-mississippi/110322mississippipbm.pdf.

FTC. 2014a. Mylan Pharmaceuticals, Inc. v. Celgene Corporation: Federal Trade Commission’s brief as amicus curiae.https://www.ftc.gov/system/files/documents/amicus_briefs/mylan-pharmaceuticals-inc.v.celgene-corporation/140617celgeneamicusbrief.pdf.

FTC. 2014b. Letter to ERISA Advisory Council. August 19. http://www.ftc.gov/system/files/documents/advocacy_documents/ftc-staff-comment-erisa-advisory-councilu.s.department-labor-regarding-pharmacy-benefit-manager-compensation-fee-disclosure/140819erisaadvisory.pdf.

Fung, A., M. Graham, and D. Weil. 2007. Full disclosure: The perils and promise of transparency. Cambridge, UK: Cambridge University Press.

Gabriel, J. M. 2014. Medical monopoly: Intellectual property rights and the origins of the modern pharmaceutical industry. Chicago: University of Chicago Press.

Gagne, J. J., and N. K. Choudhry. 2011. How many “me-too” drugs is too many? JAMA 305(7):711–712.

GAO (U.S. Government Accountability Office). 2007. Prescription drugs: An overview of approaches to negotiate drug prices used by other countries and U.S. private payers and federal programs. Washington, DC: U.S. Government Accountability Office.

Garber, A. M., and M. B. McClellan. 2007. Satisfaction guaranteed—“Payment by results” for biologic agents. New England Journal of Medicine 357(16):1575–1577.

Garber, A. M., and C. E. Phelps. 1997. Economic foundations of cost-effectiveness analysis. Journal of Health Economics 16(1):1–31.

Gesme, D. H., and M. Wiseman. 2011. Strategic use of clinical pathways. Journal of Oncology Practice 7(1):54–56.

Gibson, T. B., R. Maclean, M. E. Chernew, A. M. Fendrick, and C. Baigel. 2015. Value-based insurance design: Benefits beyond cost and utilization. The American Journal of Managed Care 21(1):32–35.

Goldberg, R. 2017. Reduce drug prices by eliminating PBM rebates. The Hill, February 14. http://thehill.com/blogs/congress-blog/healthcare/319479-reduce-drug-prices-byeliminating-pbm-rebates.

Goodman, S., and K. Dickersin. 2011. Metabias: A challenge for comparative effectiveness research. Annals of Internal Medicine 155(1):61–62.

Grabowski, H., C. Brain, A. Taub, and R. Guha. 2017. Pharmaceutical patent challenges: Company strategies and litigation outcomes. American Journal of Health Economics 3(1):33–59.

Happe, L. E., D. Clark, E. Holliday, and T. Young. 2014. A systematic literature review assessing the directional impact of managed care formulary restrictions on medication adherence, clinical outcomes, economic outcomes, and health care resource utilization. Journal of Managed Care Pharmacy 20(7):677–684.

Helland, E., and S. A. Seabury. 2016. Are settlements in patent litigation collusive? Evidence from Paragraph IV challenges. No. w22194. Cambridge, MA: National Bureau of Economic Research.

Hemphill, C. S., and B. N. Sampat. 2012. Evergreening, patent challenges, and effective market life in pharmaceuticals. Journal of Health Economics 31(2):327–339.

Hopkins, J., and Z. Tracer. 2017. Blame game over high drug prices escalates with new ad. Bloomberg, April 6. http://www.bloomberg.com/news/articles/2017-04-06/blame-gameover-high-drug-prices-gets-worse-with-lobby-s-new-ad.

Howard, D. H., J. Kauh, and J. Lipscomb. 2010. The value of new chemotherapeutic agents for metastatic colorectal cancer. Archives of Internal Medicine 170(6):537–542.

Huskamp, H. A., and N. L. Keating. 2005. The new Medicare drug benefit: Formularies and their potential effects on access to medications. Journal of General Internal Medicine 20(7):662–665.

ICER (Institute for Clinical and Economic Review). 2017. Membership. https://icer-review.org/about/membership.

IOM (Institute of Medicine). 2010. A national cancer clinical trials system for the 21st century: Reinvigorating the NCI cooperative group program. Washington, DC: The National Academies Press.

IOM. 2011. Finding what works in health care: Standards for systematic reviews. Washington, DC: The National Academies Press.

IOM. 2012. Accelerating the development of new drugs and diagnostics: Maximizing the impact of the cures acceleration network: Workshop summary. Washington, DC: The National Academies Press.

IOM. 2015a. Sharing clinical trial data: Maximizing benefits, minimizing risk. Washington, DC: The National Academies Press.

IOM. 2015b. Policy issues in the development and adoption of biomarkers for molecularly targeted cancer therapies: Workshop summary. Washington, DC: The National Academies Press.

Jones, G. H., M. A. Carrier, R. T. Silver, and H. Kantarjian. 2016. Strategies that delay or prevent the timely availability of affordable generic drugs in the United States. Blood 127(11):1398–1402.

Jung, J. K., R. Feldman, C. Cheong, P. Du, and D. Leslie. 2016. Coverage for hepatitis C drugs in Medicare Part D. American Journal of Managed Care 22(6 Spec No.):SP220–SP226.

Juthani, V. V., E. Clearfield, and R. S. Chuck. 2017. Non-steroidal anti-inflammatory drugs versus corticosteroids for controlling inflammation after uncomplicated cataract surgery. The Cochrane Library 7:CD010516.

Kanavos, P., W. Schurer, and S. Vogler. 2011. The pharmaceutical distribution chain in the European Union: Structure and impact on pharmaceutical prices.http://eprints.lse.ac.uk/51051/1/Kanavos_pharmaceutical_distribution_chain_2007.pdf.

Kesselheim, A. S., and M. M. Mello. 2006. Medical-process patents—monopolizing the delivery of health care. New England Journal of Medicine 355(19):2036–2041.

Kesselheim, A. S., M. A. Fischer, and J. Avorn. 2006. Extensions of intellectual property rights and delayed adoption of generic drugs: Effects on Medicaid spending. Health Affairs 25(6):1637–1647.

Kesselheim, A., L. Murtagh, and M. Mello. 2011. “Pay for delay” settlements of disputes over pharmaceutical patents. New England Journal of Medicine 365(15):1439–1445.

KFF (Kaiser Family Foundation) and Health Research & Educational Trust. 2017. Kaiser/HRET survey of employer-sponsored health benefits.http://files.kff.org/attachment/Report-Employer-Health-Benefits-Annual-Survey-2017.

Kirchhoff, S. M. 2015. Specialty drugs: Background and policy concerns. R44132. Washington, DC: Congressional Research Service.

Lakdawalla, D. N., E. C. Sun, A. B. Jena, C. M. Reyes, D. P. Goldman, and T. J. Philipson. 2010. An economic evaluation of the war on cancer. Journal of Health Economics 29(3):333–346.

Lee, J. L., M. L. Maciejewski, S. S. Raju, W. H. Shrank, and N. K. Choudhry. 2013. Value-based insurance design: Quality improvement but no cost savings. Health Affairs 32(7):1251–1257.

LeWitt, P. A., and S. Kim. 2015. The pharmacodynamics of placebo. Neurology 84:766–767.

Lichtenberg, F. R. 2009. The effect of new cancer drug approvals on the life expectancy of American cancer patients, 1978–2004. Economics of Innovation and New Technology 18(5):407–428.

Mandelblatt, J. S., S. D. Ramsey, T. A. Lieu, and C. E. Phelps. 2017. Evaluating frameworks that provide value measures for health care interventions. Value in Health 20(2):185–192.

Martin, A. B., M. Hartman, B. Washington, A. Catlin, and N. H. E. A. Team. 2016. National health spending: Faster growth in 2015 as coverage expands and utilization increases. Health Affairs. doi: 10.1377/hlthaff.2016.1330.

Mattioli, D., S. Terlep, and A. W. Mathews. 2017. CVS makes blockbuster Aetna bid.https://www.wsj.com/articles/cvs-health-is-in-talks-to-buy-aetna-sources-1509047642.

Mayo-Wilson, E., P. Doshi, and K. Dickersin. 2015. Are manufacturers sharing data as promised? British Medical Journal 351:h4169.

McKinsey & Company. 2013. Beyond the storm: Launch excellence in the new normal. New York: McKinsey & Company.

MedPAC (Medicare Payment Advisory Commission). 2016. Overview of Medicare drug spending. http://www.medpac.gov/docs/default-source/fact-sheets/overview-of-medicaredrug-spending.pdf?sfvrsn=0.

Neumann, P. J., and J. T. Cohen. 2015. Measuring the value of prescription drugs. New England Journal of Medicine 373(27):2595–2597.

Neumann, P. J., A. B. Rosen, and M. C. Weinstein. 2005. Medicare and cost-effectiveness analysis. New England Journal of Medicine 353(14):1516–1522.

Neumann, P. J., M. S. Kamae, and J. A. Palmer. 2008. Medicare’s national coverage decisions for technologies, 1999–2007. Health Affairs 27(6):1620–1631.

Neumann, P. J., G. D. Sanders, L. B. Russell, J. E. Siegel, and T. G. Ganiats. 2016. Cost-effectiveness in health and medicine. Second edition. New York: Oxford University Press.

Newhouse, J. P. 1993. Free for all? Lessons from the RAND health insurance experiment. Cambridge, MA: Harvard University Press.

Ng, R. 2015. Drugs: From discovery to approval. New York: John Wiley & Sons.

Novartis. 2017. Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah™ (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice. https://novartis.gcs-web.com/novartis-receivesfda-approval-for-KymriahTM.

NRC (National Research Council). 1985. Sharing research data. Washington, DC: National Academy Press.

NRC. 1989. The responsible conduct of research in the health sciences. Washington, DC: National Academy Press.

NRC. 2011. Managing university intellectual property in the public interest. Washington, DC: The National Academies Press.

OECD (Organisation for Economic Co-operation and Development). 2009. Monopsony and buyer power. DAF/COMP(2008)38. http://www.fne.gob.cl/wp-content/uploads/2014/03/OECD-2008-Monopsony-and-buyer-power.pdf.

Ollove, M. 2016. Are states obligated to provide expensive hepatitis C drugs?http://www.pewtrusts.org/en/research-and-analysis/blogs/stateline/2016/02/09/are-states-obligated-to-provide-expensive-hepatitis-c-drugs.

Page, M., J. McKenzie, K. Dwan, J. Kirkham, S. Green, and A. Forbes. 2012. Bias due to selective inclusion and reporting of outcomes and analyses in systematic reviews of randomized trials of healthcare interventions (protocol). Cochrane Database Systematic Review Oct 1(10):MR000035.

Perkins Coie LLP. 2016. Recent court cases interpreting “reverse payments” post-Actavis. http://www.perkinscoie.com/en/news-insights/recent-court-cases-interpreting-reversepayments-post-actavis.html.

Pham-Kanter, G. 2014. Act II of the Sunshine Act. PLOS Medicine 11(11):e1001754.

Phelps, C. E., and G. Madhavan. 2017. Using multicriteria approaches to assess the value of health care. Value in Health 20(2):251–255.

Phelps, C., G. Madhavan, R. Rappuoli, R. Colwell, and H. Fineberg. 2017. Beyond cost-effectiveness: Using systems analysis for infectious disease preparedness. Vaccine 35: A46–A49.

Polinski, J. M., P. E. Mohr, and L. Johnson. 2009. Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis. Arthritis Care & Research 61(6):745–754.

Pollack, A. 2014. AbbVie deal heralds changed landscape for hepatitis drugs.https://www.nytimes.com/2014/12/22/business/pharmacy-deal-heralds-changed-landscape-for-hepatitisdrugs.html?_r=0.

QuintilesIMS. 2014. Understanding the pharmaceutical value chain. Parsippany, NJ: QuintilesIMS Institute.

QuintilesIMS. 2016. Medicines use and spending in the U.S.: A review of 2015 and outlook to 2020. Parsippany, NJ: QuintilesIMS Institute.

Rawlins, M., D. Barnett, and A. Stevens. 2010. Pharmacoeconomics: NICE’s approach to decision-making. British Journal of Clinical Pharmacology 70(3):346–349.

Rosenbaum, S., and J. H. Thorpe. 2010. Comparative effectiveness research and health reform: Implications for public health policy and practice. Public Health Reports 125(6):909–912.

Rubin, R. 2016. Value pricing for drugs: Whose value, what price? http://healthaffairs.org/blog/2016/03/28/value-pricing-for-drugs-whose-value-what-price.

Rumore, M. M. 2009. The Hatch–Waxman Act—25 years later: Keeping the pharmaceutical scales balanced. Pharmacy Times, August 15. http://www.pharmacytimes.com/publications/supplement/2009/genericsupplement0809/generic-hatchwaxman-0809.

Saldanha, I. J., T. Li, C. Yang, J. Owczarzak, P. R. Williamson, and K. Dickersin. 2017. Clinical trials and systematic reviews addressing similar interventions for the same condition do not consider similar outcomes to be important: A case study in HIV/AIDS. Journal of Clinical Epidemiology 84:85–94.

Schacht, W. H. 2009. The Bayh–Dole Act: Selected issues in patent policy and the commercialization of technology. Library of Congress. Washington, DC: Congressional Research Service.

Shepherd, J. 2014. Written testimony for the ERISA Advisory Council Hearing on PBM Compensation and Fee Disclosure.

Shih, C., J. Schwartz, and A. Coukell. 2016. How would government negotiation of Medicare Part D drug prices work?http://www.healthaffairs.org/do/10.1377/hblog20160201.052912/full.

Sood, N., K. Van Nuys. T. Shih, and D. Goldman. 2017. Follow the money: The flow of funds in the pharmaceutical distribution system.http://healthpolicy.usc.edu/documents/USC%20Schaeffer_Flow%20of%20Money_2017.pdf.

Sorenson, C., G. Lavezzari, G. Daniel, R. Burkholder, M. Boutin, E. Pezalla, G. Sanders, and M. McClellan. 2017. Advancing value assessment in the United States: A multistakeholder perspective. Value in Health 20(2):299–307.

Stewart, L. A., and M. K. Parmar. 1993. Meta-analysis of the literature or of individual patientdata: Is there a difference? The Lancet 341(8842):418–422.

Stuard, S., J. Beyer, M. Bonetto, R. Driver, and N. Pinson. 2016. Summary report: State Medicaid Alternative Reimbursement and Purchasing Test for High-Cost Drugs (SMART-D). Portland, OR: Center for Evidence-based Policy, Oregon Health & Science University.

Sussex, J., A. Towse, and N. Devlin. 2013. Operationalizing value-based pricing of medicines. Pharmacoeconomics 31(1):1–10.

Tracer, Z. 2017. Aetna, Humana abandon $37 billion merger blocked by judge. https://www.bloomberg.com/news/articles/2017-02-14/aetna-humana-abandon-37-billion-merger-blocked-by-u-s-judge-iz5hjt3b.

UnitedHealth Group. 2017. Optum and Merck collaborate to advance value-based contracting of pharmaceuticals. http://www.unitedhealthgroup.com/Newsroom/Articles/Feed/Optum/2017/0525OptumLearningLab.aspx.

Van Norman, G. A. 2016. Drugs, devices, and the FDA: Part 1: An overview of approval processes for drugs. JACC: Basic to Translational Science 1(3):170–179.

Vandervelde, A., and E. Blalock. 2017. The pharmaceutical supply chain: Gross drug expenditures realized by stakeholders. Berkeley Research Group. http://www.thinkbrg.com/media/publication/863_Vandervelde_PhRMA-January-2017_WEB-FINAL.pdf.

Walker, J. 2016. Drugmakers point finger at middlemen for rising drug prices. The Wall Street Journal, October 3. http://www.wsj.com/articles/drugmakers-point-finger-at-middlemenfor-rising-drug-prices-1475443336.

WHO (World Health Organization). 2015. Access to new medicines in Europe: Technical review of policy initiatives and opportunities for collaboration and research. http://apps.who.int/medicinedocs/documents/s21793en/s21793en.pdf.

Wilensky, G. R. 2016a. “Negotiating” drug prices for Medicare. Healthcare Financial Management 70(3):32–34.

Wilensky, G. R. 2016b. Prescription drug pricing is not just an election issue. The Milbank Quarterly 94(4):712–715.

Woodward, R. M., M. L. Brown, S. T. Stewart, K. A. Cronin, and D. M. Cutler. 2007. The value of medical interventions for lung cancer in the elderly. Cancer 110(11):2511–2518.

Yazdany, J., R. A. Dudley, R. Chen, G. A. Lin, and C. W. Tseng. 2015. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D. Arthritis & Rheumatology 67(6):1474–1480.

Zon, R. T., J. N. Frame, M. N. Neuss, R. D. Page, D. S. Wollins, S. Stranne, and L. D. Bosser-man. 2016. American society of clinical oncology policy statement on clinical pathways in oncology. Journal of Oncology Practice 12(3):261–266.

CHAPTER 3

340B Health. 2016. 340B program helps hospitals provide services to vulnerable patients: Results from a survey of 340B health members. http://www.340bhealth.org/files/Savings_Survey_Report.pdf.

AASLD-IDSA (American Association for the Study of Liver Diseases and Infectious Diseases Society of America). 2017. HCV guidance: Recommendations for testing, managing, and treating hepatitis C. https://www.hcvguidelines.org/sites/default/files/full-guidance-pdf/HCVGuidance_September_21_2017_e.pdf.

Abernethy, A. P., R. R. Coeytaux, K. Carson, D. McCrory, S. Y. Barbour, M. Gradison, R. J. Irvine, and J. L. Wheeler. 2010. Report on the evidence regarding off-label indications for targeted therapies used in cancer treatment. Rockville, MD: Agency for Healthcare Research and Quality.

Adams, A. S., S. B. Soumerai, and D. Ross-Degnan. 2001. The case for a Medicare drug coverage benefit: A critical review of the empirical evidence. Annual Review of Public Health 22(1):49–61.

AIER (American Institute for Economic Research). 2017. Delinquency rates rise for student loans, credit cards, and auto loans. https://www.aier.org/blog/delinquency-rates-risestudent-loans-credit-cards-and-auto-loans.

Aitken, M., E. R. Berndt, D. Cutler, M. Kleinrock, and L. Maini. 2016. Has the era of slow growth for prescription drug spending ended? Health Affairs 35(9):1595–1603.

Alexander, G. C., L. P. Casalino, and D. O. Meltzer. 2003. Patient–physician communication about out-of-pocket costs. JAMA 290(7):953–958.

Allan, G. M., J. Lexchin, and N. Wiebe. 2007. Physician awareness of drug cost: A systematic review. PLOS Medicine 4(9):e283.

Allen, M. 2017. America’s other drug problem. http://www.propublica.org/article/americasother-drug-problem.

Alpert, A., D. Lakdawalla, and N. Sood. 2015. Prescription drug advertising and drug utilization: The role of Medicare Part D. Cambridge, MA: National Bureau of Economic Research.

AMA (American Medical Association). 2015. AMA calls for ban on direct-to-consumer advertising of prescription drugs and medical devices. November 17. http://www.ama-assn.org/content/ama-calls-ban-direct-consumer-advertising-prescription-drugs-and-medical-devices.

America’s Health Insurance Plans. 2015. Specialty drugs: Issues and challenges: Advancing effective strategies to address soaring drug costs while ensuring access to effective treatments and promoting continued medical innovation.https://www.ahip.org/wp-content/uploads/2015/07/IssueBrief_SpecialtyDrugs_7.9.15.pdf.

ASHSP (American Society of Health-System Pharmacists). 2017. Drug shortages statistics. https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortages-Statistics.

ASPE (Office of Assistant Secretary for Planning and Evaluation). 2011. Economic analysis of the causes of drug shortages. Issue brief, October 28. https://aspe.hhs.gov/report/economic-analysis-causes-drug-shortages.

Association of the British Pharmaceutical Industry. 2017. Understanding the pharmaceutical price regulation scheme (PPRS). http://www.abpi.org.uk/our-work/commercial/pprs/Pages/default.aspx.

Avorn, J. 2015. The $2.6 billion pill—Methodologic and policy considerations. New England Journal of Medicine 372(20):1877–1879.

Bach, P. B. 2009. Limits on Medicare’s ability to control rising spending on cancer drugs. New England Journal of Medicine 360(6):626–633.

Bach, P. B., R. M. Conti, R. J. Muller, G. C. Schnorr, and L. B. Saltz. 2016. Overspending driven by oversized single dose vials of cancer drugs. BMJ (Online) 352:i788.

Bai, G., and G. F. Anderson. 2016. A more detailed understanding of factors associated with hospital profitability. Health Affairs 35(5):889–897.

Baker, L. C., M. K. Bundorf, and D. P. Kessler. 2014. Vertical integration: Hospital ownership of physician practices is associated with higher prices and spending. Health Affairs 33(5):756–763.

Barua, S., R. Greenwald, J. Grebely, G. J. Dore, T. Swan, and L. E. Taylor. 2015. Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Annals of Internal Medicine 163(3):215–223.

Belk, D. 2017. Pharmaceutical financial index. http://truecostofhealthcare.org/pharmaceutical_financial_index.

Bennette, C. S., C. Richards, S. D. Sullivan, and S. D. Ramsey. 2016. Steady increase in prices for oral anticancer drugs after market launch suggests a lack of competitive pressure. Health Affairs 35(5):805–812.

Berndt, E. R., and M. L. Aitken. 2011. Brand loyalty, generic entry and price competition in pharmaceuticals in the quarter century after the 1984 Waxman–Hatch legislation. International Journal of the Economics of Business 18(2):177–201.

Berndt, E. R., and J. P. Newhouse. 2012. Pricing and reimbursement in U.S. pharmaceutical markets. In P. M. Danzon and S. Nicholson (eds.), Oxford Handbook of the Economics of the Biopharmaceutical Industry. Cambridge, UK: Oxford University Press. Pp. 201–265.

Berndt, E. R., R. M. Conti, and S. J. Murphy. 2017a. The Generic Drug User Fee Amendments: An economic perspective. No. w23642. Cambridge, MA: National Bureau of Economic Research.

Berndt, E. R., R. M. Conti, and S. J. Murphy. 2017b. The landscape of U.S. generic prescription drug markets, 2004–2016. No. w23640. Cambridge, MA: National Bureau of Economic Research.

Bhosle, M. J., and R. Balkrishnan. 2007. Drug reimportation practices in the United States. Therapeutics and Clinical Risk Management 3(1):41–46.

Bluth, R. 2017. Should the U.S. make it easier to import prescription drugs?http://www.pbs.org/newshour/rundown/u-s-make-easier-import-prescription-drugs.

Boehm, G., L. Yao, L. Han, and Q. Zheng. 2013. Development of the generic drug industry in the U.S. after the Hatch–Waxman Act of 1984. Acta Pharmaceutica Sinica B 3(5):297–311.

Brennan, T., and W. Shrank. 2014. New expensive treatments for hepatitis C infection. JAMA 312(6):593–594.

Cantrell, F. L., P. Cantrell, A. Wen, and R. Gerona. 2017. Epinephrine concentrations in epipens after the expiration date. Annals of Internal Medicine 166(12):918–919.

Cantrell, L., J. R. Suchard, A. Wu, and R. R. Gerona. 2012. Stability of active ingredients in long-expired prescription medications. Archives of Internal Medicine 172(21):1685–1687.

CBO (U.S. Congressional Budget Office). 2003. The Pharmaceutical Market Access Act of 2003 (H.R. 2427). https://www.cbo.gov/sites/default/files/108th-congress-2003-2004/costestimate/hr24270.pdf.

CBO. 2008. Congressional Budget Office cost estimate: Biologics Price Competition and Innovation Act of 2007. June 25. Washington, DC: Congressional Budget Office. https://www.cbo.gov/sites/default/files/cbofiles/ftpdocs/94xx/doc9496/s1695.pdf.

CBO. 2011. Potential effects of a ban on direct-to-consumer advertising of new prescription drugs. May 26. Washington, DC: Congressional Budget Office. https://www.cbo.gov/publication/41449.

CDC (Centers for Disease Control and Prevention). 2017a. New hepatitis C infections nearly tripled over five years.https://www.cdc.gov/nchhstp/newsroom/2017/HepatitisSurveillance-Press-Release.html.

CDC. 2017b. Ohio—State health profile.https://www.cdc.gov/nchhstp/stateprofiles/pdf/ohio_profile.pdf.

Center for Health Law and Policy. 2017. Hepatitis C: The state of Medicaid access. 2017 national summary report.https://stateofhepc.org/wp-content/uploads/2017/10/State-ofHepC_2017_FINAL.pdf.

Chen, S. I., E. R. Fox, M. K. Hall, J. S. Ross, E. M. Bucholz, H. M. Krumholz, and A. K. Venkatesh. 2016. Despite federal legislation, shortages of drugs used in acute care settings remain persistent and prolonged. Health Affairs 35(5):798–804.

Chimonas, S., N. J. DeVito, and D. J. Rothman. 2017. Bringing transparency to medicine: Exploring physicians’ views and experiences of the Sunshine Act. American Journal of Bioethics 17(6):4–18.

Chopra, S. 2014. Clinical manifestations and natural history of chronic hepatitis C virus infection. UpToDate. https://www.uptodate.com/contents/clinical-manifestations-and-naturalhistory-of-chronic-hepatitis-c-virus-infection.

Claxton, G., M. Rae, M. Long, A. Damico, and B. Sawyer. 2016. Employer health benefits: 2016 annual survey. Menlo Park, CA: Kaiser Family Foundation.

CMS (Centers for Medicare & Medicaid Services). 2016. Hospital Outpatient Prospective Payment–Proposed Rule and Proposed CY2017 Payment Rates; Federal Register 81(219):79562.

CMS. 2017a. Medicaid drug rebate program. https://www.medicaid.gov/medicaid/prescriptiondrugs/medicaid-drug-rebate-program/index.html.

CMS. 2017b. Disproportionate share hospital. http://www.cms.gov/medicare/medicare-fee-forservice-payment/acuteinpatientpps/dsh.html.

Coggins, M. D. 2016. Medication disposal challenges in LTC. Today’s Geriatric Medicine 9(1):8.

Cohen, J., A. Malins, and Z. Shahpurwala. 2013. Compared to U.S. practice, evidence-based reviews in Europe appear to lead to lower prices for some drugs. Health Affairs 32(4):762–770.

Consumer Reports. 2016. Is there a cure for high drug prices? Consumer Reports, July 29. http://www.consumerreports.org/drugs/cure-for-high-drug-prices.

Conti, R. M., and P. B. Bach. 2013. Cost consequences of the 340B drug discount program. JAMA 309(19):1995–1996.

Conti, R. M., and P. B. Bach. 2014. The 340B drug discount program: Hospitals generate profits by expanding to reach more affluent communities. Health Affairs 33(10):1786–1792.

Conti, R. M., M. B. Rosenthal, B. N. Polite, P. B. Bach, and Y.-C. T. Shih. 2012. Infused chemotherapy use in the elderly after patent expiration. Journal of Oncology Practice 8(3S):e18s–e23s.

Conti, R. M., A. C. Bernstein, V. M. Villaflor, R. L. Schilsky, M. B. Rosenthal, and P. B. Bach. 2013. Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists. Journal of Clinical Oncology 31(9):1134–1139.

Court, E. 2017. Top Celgene cancer drugs now 20% more expensive after latest price hikes.http://www.morningstar.com/news/market-watch/TDJNMW_20171023437/top-celgenecancer-drugs-now-20-more-expensive-after-latest-price-hikes.html.

Cox, C. 2016. What are recent trends and characteristics of workers with high drug spending?https://www.healthsystemtracker.org/chart-collection/recent-trendscharacteristics-workers-high-drug-spending/?_sf_s=recent#item-majority-peopleemployer-coverage-little-no-retail-drug-spending-3-9-exceed-5000-drug-spending.

CRS (Congressional Research Service). 2008. Prescription drug importation: A legal overview (RL32191). https://www.everycrsreport.com/reports/RL32191.html.

Cutler, D. M., and F. Scott. Morton. 2013. Hospitals, market share, and consolidation. JAMA 310(18):1964–1970.

Dafny, L., C. Ody, and M. Schmitt. 2016a. When discounts raise costs: The effect of copay coupons on generic utilization. No. w22745. Cambridge, MA: National Bureau of Economic Research.

Dafny, L. S., C. J. Ody, and M. A. Schmitt. 2016b. Undermining value-based purchasing—Lessons from the pharmaceutical industry. New England Journal of Medicine 375(21): 2013–2015.

Daniel, M. G., T. M. Pawlik, A. N. Fader, N. F. Esnaola, and M. A. Makary. 2016. The Orphan Drug Act: Restoring the mission to rare diseases. American Journal of Clinical Oncology 39(2):210–213.

Danzon, P. M., S. J. Johnson, G. Long, and M. F. Furukawa. 2011. Commercial importation of prescription drugs in the United States: Short-run implications. Journal of Health Politics, Policy and Law 36(2):295–316.

Daubresse, M., M. Andersen, K. R. Riggs, and G. C. Alexander. 2017. Effect of prescription drug coupons on statin utilization and expenditures: A retrospective cohort study. Pharmacotherapy 37(1):12–24.

DeJong, C., T. Aguilar, C.-W. Tseng, G. A. Lin, W. J. Boscardin, and R. A. Dudley. 2016. Pharmaceutical industry-sponsored meals and physician prescribing patterns for Medicare beneficiaries. JAMA Internal Medicine 176(8):1114–1122.

Delbanco, S. F., R. Murray, R. A. Berenson, and D. K. Upadhyay. 2016. A typology of benefit designs. Washington, DC: Urban Institute.

DiMasi, J. A., H. G. Grabowski, and R. W. Hansen. 2016. Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics 47:20–33.

Diven, D. G., D. W. Bartenstein, and D. R. Carroll. 2015. Extending shelf life just makes sense. Mayo Clinic Proceedings 90(11):1471–1474.

Dolan, R. 2016. The demise of the Part B demo: Doom for value-based payment? http://healthaffairs.org/blog/2016/12/27/the-demise-of-the-Part-B-demo-doom-for-value-based-payment.

Donohue, J. M., M. Cevasco, and M. B. Rosenthal. 2007. A decade of direct-to-consumer advertising of prescription drugs. New England Journal of Medicine 357(7):673–681.

Doshi, J. A., T. Hu, P. Li, A. R. Pettit, X. Yu, and M. Blum. 2016a. Specialty tier-level cost sharing and biologic agent use in the Medicare Part D initial coverage period among beneficiaries with rheumatoid arthritis. Arthritis Care & Research 68(11):1624–1630.

Doshi, J., P. Li, H. Huo, A. Pettit, R. Kumar, B. Weiss, and S. Huntington. 2016b. High cost sharing and specialty drug initiation under Medicare Part D: A case study in patients with newly diagnosed chronic myeloid leukemia. The American Journal of Managed Care 22(4 Suppl):s78.

Duggan, M., P. Healy, and F. Scott Morton. 2008. Providing prescription drug coverage to the elderly: America’s experiment with Medicare Part D. The Journal of Economic Perspectives 22(4):69–92.

Duke, M. S., W. G. Chambliss, K. N. Gardner, and D. M. Norris. 2011. Mitigating the impact of medication shortages on public health. Journal of the American Pharmacists Association 51(5):574–576.

Dusetzina, S. B. 2016. Share of specialty drugs in commercial plans nearly quadrupled, 2003–14. Health Affairs 35(7):1241–1246.

Dusetzina, S. B., and N. L. Keating. 2015. Mind the gap: Why closing the doughnut hole is insufficient for increasing Medicare beneficiary access to oral chemotherapy. Journal of Clinical Oncology 34(4):375–380.

Dusetzina, S. B., A. N. Winn, G. A. Abel, H. A. Huskamp, and N. L. Keating. 2014. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. Journal of Clinical Oncology 32(4):306–311.

Dusetzina, S. B., R. M. Conti, L. Y. Nancy, and P. B. Bach. 2017. Association of prescription drug price rebates in Medicare Part D with patient out-of-pocket and federal spending. JAMA Internal Medicine 177(8):1185–1188.

Eckard, E. W. 1991. Competition and the cigarette TV advertising ban. Economic Inquiry 29(1):119–133.

Ellison, A. 2017. Trump administration withdraws 340b mega-guidance: 6 things to know. https://www.beckershospitalreview.com/finance/trump-administration-withdraws-340bmega-guidance-6-things-to-know.html.

EvaluatePharma. 2017. Orphan drug report 2017. http://info.evaluategroup.com/rs/607YGS-364/images/EPOD17.pdf.

FDA (U.S. Food and Drug Administration). 2015. Expiration dating and stability testing for human drug products. http://www.fda.gov/ICECI/Inspections/InspectionGuides/InspectionTechnicalGuides/ucm072919.htm.

FDA. 2017a. Generic drugs. http://www.fda.gov/Drugs/resourcesforyou/consumers/buyingusingmedicinesafely/understandinggenericdrugs/default.htm.

FDA. 2017b. Information for consumers (biosimilars). http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/biosimilars/ucm241718.htm.

FDA. 2017c. Expiration dating extension. https://www.fda.gov/EmergencyPreparedness/Counterterrorism/MedicalCountermeasures/MCMLegalRegulatoryandPolicyFramework/ucm411446.htm.

FDA. 2017d. Extended use dates provided by Pfizer to assist with emergency syringe shortages.https://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm563360.htm.

FDA. 2017e. Orphan Drug Act—Relevant excerpts. http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/ucm364750.htm.

FDA. 2017f. The Generic Drug Review Dashboard as of April 1, 2017.https://tinyurl.com/ybqky4gy.

Fein, A. 2017. The 340b program hits $16.2 billion in 2016; now 5% of U.S. drug market. http://www.drugchannels.net/2017/05/exclusive-340b-program-hits-162-billion.html.

Fischer, K. E., T. Heisser, and T. Stargardt. 2016. Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia. Health Policy 120(10):1115–1122.

Fox, E., A. Birt, K. James, H. Kokko, S. Salverson, D. Soflin, and and ASHP Expert Panel on Drug Product Shortages. 2009. ASHP guidelines on managing drug product shortages in hospitals and health systems. American Journal of Health-System Pharmacy 66(15):1399.

Fox, E. R., B. V. Sweet, and V. Jensen. 2014. Drug shortages: A complex health care crisis. In Mayo Clinic Proceedings 89(3):361–373.

Frank, R. G. 2007. The ongoing regulation of generic drugs. New England Journal of Medicine 357(20):1993–1996.

Friedman, Z. 2017. Student loan debt in 2017: A $1.3 trillion crisis. https://www.forbes.com/sites/zackfriedman/2017/02/21/student-loan-debt-statistics-2017/#3e24a9c55dab.

Fronstin, P., M.-J. Sepúlveda, and M. C. Roebuck. 2013. Medication utilization and adherence in a health savings account–eligible plan. American Journal of Managed Care 19(12):e400–e407.

FTC (Federal Trade Commission). 2013. Brief as amicus curiae, Actelion Pharmaceuticals Ltd. v. Apotex Inc., (No. 1:12-cv-05743-NLH-AMD), (D.N.J. Mar. 2013).http://www.ftc.gov/sites/default/files/documents/amicus_briefs/actelion-pharmaceuticals-ltd.etal.v.apotex-inc./130311actelionamicusbrief.pdf.

FTC. 2017. Overview of FTC actions in pharmaceutical products and distribution. Washington, DC: Health Care Division Bureau of Competition Federal Trade Commission.

Gammie, T., C. Y. Lu, and Z. U.-D. Babar. 2015. Access to orphan drugs: A comprehensive review of legislations, regulations and policies in 35 countries. PLOS ONE 10(10):e0140002.

GAO (U.S. Government Accountability Office). 2009. Brand-name prescription drug pricing: Lack of therapeutically equivalent drugs and limited competition may contribute to extraordinary price increases. GAO-10-201 December. Washington, DC: U.S. Government Accountability Office.

GAO. 2011. Drug pricing: Manufacturer discounts in the 340B program offer benefits, but federal oversight needs improvement. GAO-11-836. September. Washington, DC: U.S. Government Accountability Office.

GAO. 2014. Drug shortages: Public health threat continues, despite efforts to help ensure product availability. Washington, DC: U.S. Government Accountability Office.

GAO. 2015. Medicare Part B drugs: Action needed to reduce financial incentives to prescribe 340B drugs at participating hospitals. GAO-15-442. June. Washington, DC: U.S. Government Accountability Office.

GAO. 2016a. Drug shortages: Certain factors are strongly associated with this persistent public health challenge. Washington, DC: U.S. Government Accountability Office.

GAO. 2016b. Generic drugs under Medicare: Part D generic drug prices declined overall, but some had extraordinary price increases. GAO-16-706. August. Washington, DC: U.S. Government Accountability Office.

Goldman, D. P., G. F. Joyce, and Y. Zheng. 2007. Prescription drug cost sharing: Associations with medication and medical utilization and spending and health. JAMA 298(1):61–69.

Goozner, M. 2017. A much-needed corrective on drug development costs. JAMA Internal Medicine 177(11):1575–1576.

GPhA (Generic Pharmaceutical Association). 2015. Generic drug savings in the U.S. Seventh annual edition. http://www.gphaonline.org/media/wysiwyg/PDF/GPhA_Savings_Report_2015.pdf.

Grabowski, H., G. Long, and R. Mortimer. 2014. Recent trends in brand-name and generic drug competition. Journal of Medical Economics 17(3):207–214.

Grabowski, H., G. Long, R. Mortimer, and A. Boyo. 2016. Updated trends in U.S. brand-name and generic drug competition. Journal of Medical Economics 19(9):836–844.

Greene, J. A., G. Anderson, and J. M. Sharfstein. 2016. Role of the FDA in affordability of off-patent pharmaceuticals. JAMA 315(5):461–462.

Gu, A., A. I. Wertheimer, B. Brown, and F. T. Shaya. 2011. Drug shortages in the U.S.—Causes, impact, and strategies. INNOVATIONS in Pharmacy 2(4):Art. 60.

Gupta, R., A. S. Kesselheim, N. Downing, J. Greene, and J. S. Ross. 2016. Generic drug approvals since the 1984 Hatch–Waxman Act. JAMA Internal Medicine 176(9):1391–1393.

Hakim, A., and J. S. Ross. 2017. Obstacles to the adoption of biosimilars for chronic diseases. JAMA 317(21):2163–2164.

Harris, G. 2012. Shipments from abroad to help ease shortage of two cancer drugs. http://www.nytimes.com/2012/02/22/health/policy/fda-approves-imports-amid-shortage-of2-cancer-drugs.html.

Haustein, R., C. de Millas, A. Höer, and B. Häussler. 2012. Saving money in the European healthcare systems with biosimilars. Generics and Biosimilars Initiative Journal 1(3–4):120–126.

Health Affairs. 2014. The 340B drug discount program.http://www.healthaffairs.org/healthpolicybriefs/brief.php?brief_id=130.

Health Affairs. 2017a. Medicaid best price.http://www.healthaffairs.org/healthpolicybriefs/brief.php?brief_id=173.

Health Affairs. 2017b. Pharmacy benefit managers.http://m.healthaffairs.org/healthpolicybriefs/brief.php?brief_id=178.

Health Affairs. 2017c. The 340B drug discount program, September 14. http://www.healthaffairs.org/do/10.1377/hpb20171409.000175/full.

Helmons, P. J., J. G. Kosterink, and C. E. Daniels. 2014. Formulary compliance and pharmacy labor costs associated with systematic formulary management strategy. American Journal of Health-System Pharmacy 71(5):407–415.

HHS (U.S. Department of Health and Human Services). 2016. Prescription drugs: Innovation, spending, and patient access. http://delauro.house.gov/sites/delauro.house.gov/files/Prescription-Drugs-Innovation-Spending-and-Patient-Access-12-07-16.pdf.

HHS. 2017. Medicare program: Hospital outpatient prospective payment and ambulatory surgical center payment systems and quality reporting programs. https://s3.amazonaws.com/public-inspection.federalregister.gov/2017-23932.pdf.

Hill, A., S. Khoo, J. Fortunak, B. Simmons, and N. Ford. 2014. Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clinical Infectious Diseases 58(7):928–936.

Hoadley, J., J. Cubanski, and T. Neuman. 2015. It pays to shop: Variation in out-of-pocket costs for Medicare Part D enrollees in 2016. https://www.kff.org/medicare/issue-brief/it-pays-to-shop-variation-in-out-of-pocket-costs-for-medicare-part-d-enrollees-in-2016.

Horwitz, J. R. 2005. Making profits and providing care: Comparing nonprofit, for-profit, and government hospitals. Health Affairs 24(3):790–801.

Howard, D. H., P. B. Bach, E. R. Berndt, and R. M. Conti. 2015. Pricing in the market for anticancer drugs. Journal of Economic Perspectives 29(1):139–162.

HRSA (Health Resources and Services Administration). 2017. 340B drug pricing program. http://www.hrsa.gov/opa.

Humana. 2017. More prescription tools and ways to save. http://www.humana.com/pharmacy/medicare/tools.

India Department of Pharmaceuticals. 2017. About the National Pharmaceutical Pricing Authority.http://pharmaceuticals.gov.in/dpconppa.

IOM (Institute of Medicine). 2000. America’s health care safety net: Intact but endangered. Washington, DC: National Academy Press.

IOM. 2009. Conflict of interest in medical research, education, and practice. Washington, DC: The National Academies Press.

Jacobson, M., A. J. O’Malley, C. C. Earle, J. Pakes, P. Gaccione, and J. P. Newhouse. 2006. Does reimbursement influence chemotherapy treatment for cancer patients? Health Affairs 25(2):437–443.

Jacobson, M., C. C. Earle, M. Price, and J. P. Newhouse. 2010. How Medicare’s payment cuts for cancer chemotherapy drugs changed patterns of treatment. Health Affairs 29(7):1391–1399.

Jakobsen, J. C., E. E. Nielsen, J. Feinberg, K. K. Katakam, K. Fobian, G. Hauser, G. Poropat, S. Djurisic, K. H. Weiss, and M. Bjelakovic. 2017. Direct-acting antivirals for chronic hepatitis C. The Cochrane Library 10:CD012143.

Jung, J. K., R. Feldman, C. Cheong, P. Du, and D. Leslie. 2016. Coverage for hepatitis c drugs in Medicare Part D. The American Journal of Managed Care 22(6 Spec No.): SP220–SP226.

Kaakeh, R., B. V. Sweet, C. Reilly, C. Bush, S. DeLoach, B. Higgins, A. M. Clark, and J. Stevenson. 2011. Impact of drug shortages on U.S. health systems. American Journal of Health-System Pharmacy 68(19):1811.

Kaiser Health News. 2009. CBO says allowing reimportation unlikely to reduce U.S. spending on prescription drugs. http://khn.org/morning-breakout/dr00018996.

Kamath, R., and S. McKibbin. 2003. Report on feasibility of employees and retirees safely and effectively purchasing prescription drugs from Canadian pharmacies. Springfield, IL: Office of Special Advocate for Prescription Drugs, Department of Central Management Services.

Kantarjian, H., and R. Chapman. 2015. Value of the 340B drug discount program. JAMA Oncology 1(8):1029–1030.

KEI (Knowledge Ecology International). 2014. KEI comment on the new Tufts Study on Drug Development Costs. http://keionline.org/node/2127.

Kent, A. 2007. Should patient groups accept money from drug companies? Yes. BMJ 334(7600):934.

Kesselheim, A. S., and J. Avorn. 2008. Pharmaceutical promotion to physicians and First Amendment rights. New England Journal of Medicine 358(16):1727–1732.

Kesselheim, A. S., K. F. Huybrechts, N. K. Choudhry, L. A. Fulchino, D. L. Isaman, M. K. Kowal, and T. A. Brennan. 2015. Prescription drug insurance coverage and patient health outcomes: A systematic review. American Journal of Public Health 105(2):e17–e30.

Kesselheim, A. S., J. Avorn, and A. Sarpatwari. 2016. The high cost of prescription drugs in the United States: Origins and prospects for reform. JAMA 316(8):858–871.

KFF (Kaiser Family Foundation). 2017a. No limit: Medicare Part D enrollees exposed to high out-of-pocket drug costs without a hard cap on spending. https://www.kff.org/medicare/issue-brief/no-limit-medicare-part-d-enrollees-exposed-to-high-out-of-pocket-drug-costswithout-a-hard-cap-on-spending.

KFF. 2017b. The Medicare Part D prescription drug benefit.https://www.kff.org/medicare/fact-sheet/the-medicare-prescription-drug-benefit-fact-sheet.

KFF and Health Research & Educational Trust. 2017. Kaiser/HRET survey of employer-sponsored health benefits.http://files.kff.org/attachment/Report-Employer-Health-BenefitsAnnual-Survey-2017.

King, M., and P. S. Bearman. 2017. Gifts and influence: Conflict of interest policies and prescribing of psychotropic medications in the United States. Social Science & Medicine 172:153–162.

Kohli, A., A. Shaffer, A. Sherman, and S. Kottilil. 2014. Treatment of hepatitis C: A systematic review. JAMA 312(6):631–640.

Kravitz, R. L., R. M. Epstein, M. D. Feldman, C. E. Franz, R. Azari, M. S. Wilkes, L. Hinton, and P. Franks. 2005. Influence of patients’ requests for direct-to-consumer advertised antidepressants: A randomized controlled trial. JAMA 293(16):1995–2002.

Laing, R., B. Waning, A. Gray, N. Ford, and E. T. Hoen. 2003. 25 years of the WHO essential medicines lists: Progress and challenges. The Lancet 361(9370):1723–1729.

Larkin, I., D. Ang, J. Avorn, and A. S. Kesselheim. 2014. Restrictions on pharmaceutical detailing reduced off-label prescribing of antidepressants and antipsychotics in children. Health Affairs 33(6):1014–1023.

Lauer, M. S., and R. B. D’Agostino, Sr. 2013. The randomized registry trial—The next disruptive technology in clinical research? New England Journal of Medicine 369(17):1579.

Lauterbach, K., J. J. McDonough, and E. Seeley. 2016. Germany’s model for drug price regulation could work in the U.S. Health Affairs Blog, December 29. http://healthaffairs.org/blog/2016/12/29/germanys-model-for-drug-price-regulation-could-work-in-the-us.

Lee, C.-Y., X. Chen, R. J. Romanelli, and J. B. Segal. 2016. Forces influencing generic drug development in the United States: A narrative review. Journal of Pharmaceutical Policy and Practice 9(1):26.

Lexchin, J. 2017. The relation between promotional spending on drugs and their therapeutic gain: A cohort analysis. CMAJ Open 5(3):E724–E728.

Loewenstein, G., S. Sah, and D. M. Cain. 2012. The unintended consequences of conflict of interest disclosure. JAMA 307(7):669–670.

Loughnot, D. 2005. Potential interactions of the Orphan Drug Act and pharmacogenomics: A flood of orphan drugs and abuses? American Journal of Law & Medicine 31(2–3):365–380.

Lyon, R. C., J. S. Taylor, D. A. Porter, H. R. Prasanna, and A. S. Hussain. 2006. Stability profiles of drug products extended beyond labeled expiration dates. Journal of Pharmaceutical Sciences 95(7):1549–1560.

Mackey, T. K., and B. A. Liang. 2013. Pharmaceutical digital marketing and governance: Illicit actors and challenges to global patient safety and public health. Globalization and Health 9(1):45.

Mailankody, S., and V. Prasad. 2017. Pharmaceutical marketing for rare diseases: Regulating drug company promotion in an era of unprecedented advertisement. JAMA 317(24):2479–2480.

Malin, J. L., J. C. Weeks, A. L. Potosky, M. C. Hornbrook, and N. L. Keating. 2012. Medical oncologists’ perceptions of financial incentives in cancer care. Journal of Clinical Oncology 31(5):530–535.

McConnell, K. J., and M. E. Chernew. 2017. Controlling the cost of Medicaid. New England Journal of Medicine 377(3):201–203.

McCoy, M. S., M. Carniol, K. Chockley, J. W. Urwin, E. J. Emanuel, and H. Schmidt. 2017. Conflicts of interest for patient-advocacy organizations. New England Journal of Medicine 376(9):880–885.

McGinley, L. 2017. Hospitals scramble to avert saline shortage in wake of Puerto Rico disaster. The Washington Post, October 9. https://www.washingtonpost.com/news/to-your-health/wp/2017/10/09/hospitals-scramble-to-avert-saline-shortage-in-wake-ofpuerto-rico-disaster/?utm_term=.27c3c8c7f384.

McKenna, M. 2011. Hospital pharmacists scrambling amid vast drug shortages. Annals of Emergency Medicine 57(2):A13–A15.

McMullin, S. T., T. P. Lonergan, and C. S. Rynearson. 2005. Twelve-month drug cost savings related to use of an electronic prescribing system with integrated decision support in primary care. Journal of Managed Care Pharmacy 11(4):322–332.

MedPAC (Medicare Payment Advisory Commission). 2016. Medicare and the health care delivery system. Washington, DC: MedPAC. http://medpac.gov/docs/default-source/reports/jun17_reporttocongress_sec.pdf.

MedPAC. 2017a. A data book. Health care spending and the Medicare program. Washington, DC: MedPAC. http://www.medpac.gov/docs/default-source/data-book/june-2016-databook-health-care-spending-and-the-medicare-program.pdf.

MedPAC. 2017b. Hospital inpatient and outpatient services. 2017 Report to Congress. http://www.medpac.gov/docs/default-source/reports/mar17_medpac_ch3.pdf?sfvrsn=0.

Mintzes, B. 2007. Should patient groups accept money from drug companies? No. British Medical Journal 334(7600):935.

Mogull, S. A. 2008. Chronology of direct-to-consumer advertising regulation in the United States. American Medical Writers Association Journal 23(3):106–109.

Montazerhodjat, V., D. M. Weinstock, and A. W. Lo. 2016. Buying cures versus renting health: Financing health care with consumer loans. Science Translational Medicine 8(327):327ps326.

Morgan, S., P. Grootendorst, J. Lexchin, C. Cunningham, and D. Greyson. 2011. The cost of drug development: A systematic review. Health Policy 100(1):4–17.

Mulcahy, A. W., C. Armstrong, J. Lewis, and S. Mattke. 2014a. The 340B prescription drug discount program: Origins, implementation, and post-reform future. Santa Monica, CA: RAND Corporation.

Mulcahy, A. W., Z. Predmore, and S. Mattke. 2014b. The cost savings potential of biosimilar drugs in the United States. Santa Monica, CA: RAND Corporation.

NAMD (National Association of Medicaid Directors). 2017. NAMD’s legislative priorities for 2017. http://medicaiddirectors.org/wp-content/uploads/2016/12/NAMD-Legislative-TopIssues-for-2017_FINAL.pdf.

NASEM (National Academies of Sciences, Engineering, and Medicine). 2016. Biomarker tests for molecularly targeted therapies: Key to unlocking precision medicine. Washington, DC: The National Academies Press.

NASEM. 2017. A national strategy for the elimination of hepatitis B and C: Phase two report. Washington, DC: The National Academies Press.

Nikpay S, M. Buntin, and R. Conti. 2017. The 340B program: Mandatory reporting, alternative eligibility criteria should be top priorities for Congress.https://www.healthaffairs.org/do/10.1377/hblog20171021.982593/full.

Novartis. 2017. Product sales: Full year 2016 product sales. http://www.novartis.com/investors/financial-data/product-sales.

OIG (Office of Inspector General). 2014. Medicaid drug rebate dispute resolution could be improved (OEI-05-11-00580). https://oig.hhs.gov/oei/reports/oei-05-11-00580.pdf.

Olson, L., and B. W. Wendling. 2013. The effect of generic drug competition on generic drug prices during the Hatch–Waxman 180-day exclusivity period. Working Paper No. 317. Washington, DC: Federal Trade Commission Bureau of Economics. http://www.ftc.gov/sites/default/files/documents/reports/estimating-effect-entry-generic-drug-prices-usinghatch-waxman-exclusivity/wp317.pdf.

OTA (Office of Technology Assessment). 1993. Pharmaceutical research and development: Costs, risks and rewards. Washington, DC: U.S. Government Printing Office.

Outterson, K. 2005. Pharmaceutical arbitrage: Balancing access and innovation in international prescription drug markets. Yale Journal of Health Policy, Law, and Ethics 5(1):193–291.

Paris, V., and A. Belloni. 2014. Value in pharmaceutical pricing. Country profile: Australia. OECD.https://www.oecd.org/health/Value-in-Pharmaceutical-Pricing-Australia.pdf.

Pew. 2017. Drug shortages: An exploration of the relationship between U.S. market forces and sterile injectable pharmaceutical products: Interviews with 10 pharmaceutical companies.http://www.pewtrusts.org/en/research-and-analysis/reports/2017/01/drug-shortages.

Pharmaceutical Benefits Scheme. 2017a. About the Pharmaceutical Benefits Scheme.http://www.pbs.gov.au/info/about-the-pbs.

Pharmaceutical Benefits Scheme. 2017b. Pharmaceutical Benefits Advisory Committee (PBAC) membership.http://www.pbs.gov.au/info/industry/listing/participants/pbac.

Pitts. P. 2017. A flawed study depicts drug companies as profiteers.https://www.wsj.com/articles/a-flawed-study-depicts-drug-companies-as-profiteers-1507590936.

PMPRB (Patented Medicine Prices Review Board). 2017a. About the Patented Medicine Prices Review Board.http://pmprb-cepmb.gc.ca/about-us.

PMPRB. 2017b. Price review.http://pmprb-cepmb.gc.ca/en/regulating-prices/price-review.

Polite, B. N., J. C. Ward, J. V. Cox, R. F. Morton, J. Hennessy, R. D. Page, and R. M. Conti. 2014. Payment for oncolytics in the United States: A history of buy and bill and proposals for reform. Journal of Oncology Practice 10(6):357–362.

Polite, B., R. M. Conti, and J. C. Ward. 2015. Reform of the buy-and-bill system for outpatient chemotherapy care is inevitable: Perspectives from an economist, a realpolitik, and an oncologist. American Society of Clinical Oncology Educational Book e75–e80.

Prasad, V., and S. Mailankody. 2017. Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Internal Medicine 177(11): 1569–1575.

Pringle, J. L., A. Boyer, M. H. Conklin, J. W. McCullough, and A. Aldridge. 2014. The Pennsylvania Project: Pharmacist intervention improved medication adherence and reduced health care costs. Health Affairs 33(8):1444–1452.

Pulsinelli, G. A. 1999. Orphan Drug Act: What’s right with it. Santa Clara High Technology Law Journal 15(2):299–345.

QuintilesIMS. 2015a. Medicine use and spending shifts: A review of the use of medicines in the U.S. in 2014. Parsippany, NJ: QuintilesIMS Institute.

QuintilesIMS. 2015b. Understanding the role and use of essential medicines lists. Parsippany, NJ: QuintilesIMS Institute.

QuintilesIMS. 2016a. Medicines use and spending in the U.S.: A review of 2015 and outlook to 2020. Parsippany, NJ: QuintilesIMS Institute.

QuintilesIMS. 2016b. Price declines after branded medicines lose exclusivity in the U.S. Parsippany, NJ: QuintilesIMS Institute.

QuintilesIMS. 2017a. Medicines use and spending in the U.S.: A review of 2016 and outlook to 2021. Parsippany, NJ: QuintilesIMS Institute.

QuintilesIMS. 2017b. The impact of biosimilar competition in Europe.http://www.medicinesforeurope.com/wp-content/uploads/2017/05/IMS-Biosimilar-2017_V9.pdf.

Ramalho de Oliveira, D., A. R. Brummel, and D. B. Miller. 2010. Medication therapy management: 10 years of experience in a large integrated health care system. Journal of Managed Care Pharmacy 16(3):185–195.

Reichertz, P. S., and M. S. Friend. 1999. Hiding behind agency discretion: The Food and Drug Administration’s personal use drug importation policy. Cornell Journal of Law and Public Policy 9:493–521.

Reidenberg, M. M., and T. Walley. 2004. The pros and cons of essential medicines for rich countries. British Medical Journal (Clinical Research Edition) 329(7475):1172.

Riggs, T. L. 2004. Research and development costs for drugs. The Lancet 363(9404):184.

Robins, R. 2016. Drug makers now spend $5 billion a year on advertising. Here’s what that buys.http://www.statnews.com/2016/03/09/drug-industry-advertising.

Roebuck, M. C., J. N. Liberman, M. Gemmill-Toyama, and T. A. Brennan. 2011. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Affairs 30(1):91–99.

Rosenberg, E. S., E. W. Hall, P. S. Sullivan, T. H. Sanchez, K. A. Workowski, J. W. Ward, and D. Holtzman. 2017. Estimation of state-level prevalence of hepatitis C virus infection, U.S. states and District of Columbia, 2010. Clinical Infectious Diseases 64(11):1573–1581.

Rosenthal, E. S., and C. S. Graham. 2016. Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States. Infectious Agents and Cancer 11(1):24.

Ross, J. S. 2016. Therapeutic substitution—Should it be systematic or automatic? JAMA Internal Medicine 176(6):776.

Ross, J. S. 2017. Having their cake and eating it too: Physician skepticism of the open payments program. American Journal of Bioethics 17(6):19–22.

Ross, J. S., and A. S. Kesselheim. 2013. Prescription-drug coupons—No such thing as a free lunch. New England Journal of Medicine 369(13):1188–1189.

Rothman, S. M., V. H. Raveis, A. Friedman, and D. J. Rothman. 2011. Health advocacy organizations and the pharmaceutical industry: An analysis of disclosure practices. American Journal of Public Health 101(4):602–609.

Ruof, J., F. W. Schwartz, J.-M. Schulenburg, and C.-M. Dintsios. 2014. Early benefit assessment (EBA) in Germany: Analysing decisions 18 months after introducing the new AMNOG legislation. European Journal of Health Economics 15(6):577–589.

Schondelmayer, S. W., and L. Purvis. 2016. Rx Price Watch Report: Trends in retail prices of brand name prescription drugs widely used by older Americans: 2006 to 2015. Research Report #2016-04. Washington, DC: AARP Public Policy Institute.

Schrag, D. 2016. Reimbursing wisely? CMS’s trial of Medicare Part B drug payment reform. New England Journal of Medicine 374(22):2101–2105.

Schutte, T., J. Tichelaar, P. Nanayakkara, M. Richir, and M. Agtmael. 2017. Students and doctors are unaware of the cost of drugs they frequently prescribe. Basic & Clinical Pharmacology & Toxicology 120(3):278–283.

Shahinian, V. B., Y.-F. Kuo, and S. M. Gilbert. 2010. Reimbursement policy and androgen-deprivation therapy for prostate cancer. New England Journal of Medicine 363(19): 1822–1832.

Shih, Y.-C. T., Y. Xu, L. Liu, and F. Smieliauskas. 2017. Rising prices of targeted oral anticancer medications and associated financial burden on Medicare beneficiaries. Journal of Clinical Oncology 35(22):2482–2489.

Shrank, W. H., G. Joseph, N. K. Choudhry, H. N. Young, S. L. Ettner, P. Glassman, S. M. Asch, and R. L. Kravitz. 2006a. Physicians’ perceptions of relevant prescription drug costs: Do costs to the individual patient or to the population matter most? American Journal of Managed Care 12(9):545–551.

Shrank, W. H., T. Hoang, S. L. Ettner, P. A. Glassman, K. Nair, D. DeLapp, J. Dirstine, J. Avorn, and S. M. Asch. 2006b. The implications of choice: Prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Archives of Internal Medicine 166(3):332–337.

Shrank, W. H., J. N. Liberman, M. A. Fischer, J. Avorn, E. Kilabuk, A. Chang, A. S. Kesselheim, T. A. Brennan, and N. K. Choudhry. 2011. The consequences of requesting “dispense as written.” American Journal of Medicine 124(4):309–317.

Simoens, S. 2011. Biosimilar medicines and cost-effectiveness. ClinicoEconomics and Outcomes Research 3:29–36.

Stammen, L. A., R. E. Stalmeijer, E. Paternotte, A. O. Pool, E. W. Driessen, F. Scheele, and L. P. Stassen. 2015. Training physicians to provide high-value, cost-conscious care: A systematic review. JAMA 314(22):2384–2400.

Stomberg, C. 2016. Drug shortages, pricing, and regulatory activity. In Measuring and modeling health care costs. Chicago: University of Chicago Press.

Stone, J. 2015. Growing antibiotic shortages threaten patient care. https://www.forbes.com/sites/judystone/2015/04/25/growing-antibiotic-shortages-threaten-patient-care/#1ee84a4c6aeb.

Streeter, S. B., L. Schwartzberg, N. Husain, and M. Johnsrud. 2011. Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. Journal of Oncology Practice 7(3S):46s–51s.

Tamblyn, R., T. Eguale, A. Huang, N. Winslade, and P. Doran. 2014. The incidence and determinants of primary nonadherence with prescribed medication in primary care: A cohort study. Annals of Internal Medicine 160(7):441–450.

Terry, N. P. 2004. Prescriptions sans frontières (or how I stopped worrying about Viagra on the web but grew concerned about the future of healthcare delivery). Yale Journal of Health Policy, Law, and Ethics 4(2):183–272.

Tribble, S. J., and S. Lupkin. 2017. Drugmakers manipulate orphan drug rules to create prized monopolies. http://khn.org/news/drugmakers-manipulate-orphan-drug-rules-tocreate-prized-monopolies.

Trish, E., J. Xu, and G. Joyce. 2016. Medicare beneficiaries face growing out-of-pocket burden for specialty drugs while in catastrophic coverage phase. Health Affairs 35(9):1564–1571.

Trowman, R., H. Chung, C. Longson, P. Littlejohns, and P. Clark. 2011. The National Institute for Health and Clinical Excellence and its role in assessing the value of new cancer treatments in England and Wales. Clinical Cancer Research 17(15):4930–4935.

Ubel, P. A., and P. B. Bach. 2016. Copay assistance for expensive drugs: A helping hand that raises costs. Annals of Internal Medicine 165(12):878–879.

USPSTF (U.S. Preventive Services Task Force). 2014. The guide to clinical preventive services 2014: Recommendations of the U.S. Preventive Services Task Force.https://www.ahrq.gov/professionals/clinicians-providers/guidelines-recommendations/guide/index.html.

Ventola, C. L. 2011. Direct-to-consumer pharmaceutical advertising: Therapeutic or toxic? Pharmacy and Therapeutics 36(10):669–674.

von Oehsen, W., G. Doggett, and J. Davis. 2012. The 340B drug discount program: A new era of enforcement and oversight. Journal of Health & Life Sciences Law, June 2–73.

Waldman, A. 2017. Big Pharma quietly enlists leading professors to justify $1,000-per-day drugs. ProPublica, February 23. https://www.propublica.org/article/big-pharma-quietlyenlists-leading-professors-to-justify-1000-per-day-drugs.

Wallack, M., and S. Herzog. 2011. Demonstrating the value of the 340B program to safety-net hospitals and the vulnerable patients they serve. http://www.340bhealth.org/images/uploads/340B_Value_Report_06-29-11.pdf.

Wells, J. 2017. Are cancer drugs cheaper to make than previously thought? New study claims so. https://www.acsh.org/news/2017/09/13/are-cancer-drugs-cheaper-make-previouslythought-new-study-claims-so-11819.

WHO (World Health Organization). 2015. Access to new medicines in Europe: Technical review of policy initiatives and opportunities for collaboration and research. Geneva, Switzerland: WHO Regional Office for Europe.

WHO. 2017a. Essential medicines.http://www.who.int/topics/essential_medicines/en.

WHO. 2017b. National list of essential medicines (NLEM) 2015. http://apps.who.int/medicinedocs/documents/s23088en/s23088en.pdf.

Wilkes, M. S., R. A. Bell, and R. L. Kravitz. 2000. Direct-to-consumer prescription drug advertising: Trends, impact, and implications. Health Affairs 19(2):110–128.

Winn, A. N., N. L. Keating, and S. B. Dusetzina. 2016. Factors associated with tyrosine kinase inhibitor initiation and adherence among Medicare beneficiaries with chronic myeloid leukemia. Journal of Clinical Oncology 34(36):4323–4328.

Wong, A. Y.-T., M. M. Rumore, and A. W.-K. Chan. 2017. Biosimilars in the United States: Emerging issues in litigation. BioDrugs 31(3):189–205.

Woodcock, J., and M. Wosinska. 2013. Economic and technological drivers of generic sterile injectable drug shortages. Clinical Pharmacology & Therapeutics 93(2):170–176.

Wouters, O. J., P. G. Kanavos, and M. McKEE. 2017. Comparing generic drug markets in Europe and the United States: Prices, volumes, and spending. The Milbank Quarterly 95(3):554–601.

Yazdany, J., R. A. Dudley, R. Chen, G. A. Lin, and C. W. Tseng. 2015. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D. Arthritis & Rheumatology 67(6):1474–1480.

Yeh, J. S., J. M. Franklin, J. Avorn, J. Landon, and A. S. Kesselheim. 2016. Association of industry payments to physicians with the prescribing of brand-name statins in Massachusetts. JAMA Internal Medicine 176(6):763–768.

This page intentionally left blank.